Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: aghajanian c. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. Nat Med. 2024. PMID: 38653864 Free PMC article. Clinical Trial.
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Manning-Geist B, Gordhandas S, Hodgson A, Zhou QC, Iasonos A, Chi DS, Ellenson L, Aghajanian CA, Abu-Rustum NR, Leitao M, Long K, Rubinstein MM, Sonoda Y, Alektiar K, Weigelt B, Zivanovic O, Grisham RN. Manning-Geist B, et al. Among authors: aghajanian ca. Int J Gynecol Cancer. 2022 Dec 5;32(12):1576-1582. doi: 10.1136/ijgc-2022-003935. Int J Gynecol Cancer. 2022. PMID: 36368707 Free PMC article.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. Rubinstein MM, et al. Among authors: aghajanian c. Gynecol Oncol. 2023 Feb;169:64-69. doi: 10.1016/j.ygyno.2022.11.028. Epub 2022 Dec 10. Gynecol Oncol. 2023. PMID: 36512912 Free PMC article. Clinical Trial.
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.
Manning-Geist BL, Gnjatic S, Aghajanian C, Konner J, Kim SH, Sarasohn D, Soldan K, Tew WP, Sarlis NJ, Zamarin D, Kravetz S, Laface I, Rasalan-Ho T, Qi J, Wong P, Sabbatini PJ, O'Cearbhaill RE. Manning-Geist BL, et al. Among authors: aghajanian c. Cancers (Basel). 2023 Feb 25;15(5):1458. doi: 10.3390/cancers15051458. Cancers (Basel). 2023. PMID: 36900251 Free PMC article.
Germline drivers of gynecologic carcinosarcomas.
Sia TY, Gordhandas SB, Birsoy O, Kemel Y, Maio A, Salo-Mullen E, Sheehan M, Hensley ML, Rubinstein M, Makker V, Grisham RN, O'Cearbhaill RE, Roche KL, Mueller JJ, Leitao MM Jr, Sonoda Y, Chi DS, Abu-Rustum NR, Berger MF, Ellenson LH, Latham A, Stadler Z, Offit K, Aghajanian C, Weigelt B, Mandelker D, Liu YL. Sia TY, et al. Among authors: aghajanian c. Gynecol Oncol. 2023 Jul;174:34-41. doi: 10.1016/j.ygyno.2023.04.024. Epub 2023 May 5. Gynecol Oncol. 2023. PMID: 37149903
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Praiss AM, White C, Iasonos A, Selenica P, Zivanovic O, Chi DS, Abu-Rustum NR, Weigelt B, Aghajanian C, Girshman J, Park KJ, Grisham RN. Praiss AM, et al. Among authors: aghajanian c. Gynecol Oncol. 2024 Mar;182:32-38. doi: 10.1016/j.ygyno.2024.01.015. Epub 2024 Jan 20. Gynecol Oncol. 2024. PMID: 38246044
Comprehensive analysis of germline drivers in endometrial cancer.
Gordhandas S, Rios-Doria E, Cadoo KA, Catchings A, Maio A, Kemel Y, Sheehan M, Ranganathan M, Green D, Aryamvally A, Arnold AG, Salo-Mullen E, Manning-Geist B, Sia T, Selenica P, Da Cruz Paula A, Vanderbilt C, Misyura M, Leitao MM, Mueller JJ, Makker V, Rubinstein M, Friedman CF, Zhou Q, Iasonos A, Latham A, Carlo MI, Murciano-Goroff YR, Will M, Walsh MF, Issa Bhaloo S, Ellenson LH, Ceyhan-Birsoy O, Berger MF, Robson ME, Abu-Rustum N, Aghajanian C, Offit K, Stadler Z, Weigelt B, Mandelker DL, Liu YL. Gordhandas S, et al. Among authors: aghajanian c. J Natl Cancer Inst. 2023 May 8;115(5):560-569. doi: 10.1093/jnci/djad016. J Natl Cancer Inst. 2023. PMID: 36744932 Free PMC article.
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer.
Sia TY, Maio A, Kemel YM, Arora KS, Gordhandas SB, Kahn RM, Salo-Mullen EE, Sheehan MA, Tejada PR, Bandlamudi C, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, Tew WP, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, Chi DS, Latham AJ, Carlo MI, Murciano-Goroff YR, Will M, Walsh MF, Robson ME, Mandelker DL, Berger MF, Abu-Rustum NR, Brown CL, Offit K, Hamilton JG, Aghajanian C, Weigelt B, Stadler ZK, Liu YL. Sia TY, et al. Among authors: aghajanian c. JCO Precis Oncol. 2023 Sep;7:e2300137. doi: 10.1200/PO.23.00137. JCO Precis Oncol. 2023. PMID: 37738546
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA 3rd, Ma W, Espino K, Gordhandas S, Yeoshoua E, Ehmann S, Zhou Q, Iasonos A, Abu-Rustum NR, Aghajanian C, Green AK, Rubinstein MM, Makker V. Zammarrelli WA 3rd, et al. Among authors: aghajanian c. Gynecol Oncol. 2023 Nov;178:27-35. doi: 10.1016/j.ygyno.2023.09.010. Epub 2023 Sep 23. Gynecol Oncol. 2023. PMID: 37748268
302 results